Dicerna Pharma (DRNA) Tops Q3 EPS by 17c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Dicerna Pharma (DRNA) Tops Q3 EPS by 17c

Dicerna Reports Third Quarter 2016 Financial and Operational Results

November 7, 2016 4:06 PM EST

Management to Host Conference Call Today at 4:30 p.m. ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the third quarter ended September 30, 2016.

This quarter, we made the strategic decision to focus our resources on advancing our GalXC subcutaneous RNAi technology platform and to prioritize the product candidates emerging from this powerful product engine, said Douglas Fambrough, Ph.D., president and chief executive officer of Dicerna. Our decision was based on the... More